MRNA Stock Jumps on CDC's Revised RSV Vaccine Recommendations

Shares of Moderna MRNA rose nearly 6% yesterday after the U.S. Centers for Disease Control and Prevention (“CDC”) adopted new recommendations for the use of RSV vaccines in the upcoming respiratory virus season.The revised recommendations lower the recommended age for RSV vaccination. Now, adults aged 50-59 who are at higher...